Navigation Links
Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
Date:5/8/2008

y patient diaries during the treatment periods using the Brief Pain Inventory (BPI); and pre- and post-treatment scores using the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index of pain, stiffness and function. Plasma levels were evaluated for morphine sulfate and naltrexone pre-dose and at specified intervals up to 12 hours post-dose on days seven and 14 of the treatment periods, and at the end of the study. Follow-up calls with patients a further seven days after the end of the study were conducted to assess the occurrence of any adverse events.

During treatment, ALO-01 was similar to extended-release morphine sulfate for mean pain intensity (2.3 to 2.4 at Day 14) and BPI (average 2.1 to 2.2). WOMAC scores were also comparable with composite indices of 24.5 for ALO-01 and 26.6 for extended-release morphine sulfate. Plasma concentrations of morphine were similar over time, and naltrexone levels at the end of each treatment period below a quantifiable limit for most patients (82.1 percent). In patients with detectable levels of naltrexone, there was no impact on pain scores. Adverse events were mostly mild to moderate, and included constipation (15.5 percent and 12.7 percent), nausea and somnolence (both 9.9 percent and 8.5 percent) for ALO-01 and extended-release morphine sulfate, respectively.

Statements made in this release include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Information on other important potential risks and uncertainties not discussed herein may be found in the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2007.

About Alpharma

Alpharma Inc. (NYSE: '/>"/>

SOURCE Alpharma Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
2. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
3. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
4. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
7. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
8. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
9. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
10. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
11. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli Lilly ... of its long-standing technology transfer program to increase the ... in 2003, the effort included Lilly donating manufacturing technology ... China , India ... South Africa – all MDR-TB ,hot spots., ...
(Date:10/27/2014)... 27, 2014 Research and Markets has ... 2014-2018" report to their offering. H1N1 ... a variant of the swine H1N1 virus, known as H1N1v ... nose, throat, and lungs. H1N1 virus is an RNA virus ... animal species such as humans, swine, birds, seals, and horses. ...
(Date:10/27/2014)... EAST TAUNTON, Mass. , Oct. 27, 2014 /PRNewswire/ ... the $15 billion global hip and knee replacement device market, ... and knee replacement technology at the American Association of ... the Sheraton Dallas Hotel in Dallas, Texas ... is a Bronze corporate partner of the organization. ...
Breaking Medicine Technology:Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 2OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 3
... Bulletin Board: GOVX ) announced today the publication ... its HIV/AIDS vaccine products. The article, titled "Phase 1 Safety ... Vaccines Expressing HIV-1 Virus-like Particles," will appear in the March ... Diseases . A PDF of the article is available at ...
... Inc., a leader in room temperature biostability technology, ... (IQT). IQT is the independent, strategic investment firm ... mission of the U.S. Intelligence Community. ... pioneered recent innovations in ambient storage of biological ...
Cached Medicine Technology:GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 2GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 3GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 4Biomatrica Secures Strategic Investment from IQT 2Biomatrica Secures Strategic Investment from IQT 3
(Date:10/30/2014)... Steven Reinberg HealthDay Reporter , ... to men with prostate cancer who also have certain heart ... cause, a new study suggests. , , The therapy in question ... cancer to reduce levels of male hormones to prevent the ... the current research, this hormone therapy was linked to triple ...
(Date:10/30/2014)... Home Care Assistance – Halton/Peel Region ( http://www.GreaterTorontoHomeCare.ca ... care, is weighing in on a recent study linking ... performed by the University of Illinois, analyzed 88 patients ... week-long period and observed how much time was spent ... the structural soundness of the white matter in each ...
(Date:10/30/2014)... San Francisco, California (PRWEB) October 30, 2014 ... 5.75 billion by 2020, according to a new study ... consumption, coupled with surging demand for sugar and fat ... expected to augment the demand for prebiotics over the ... http://www.grandviewresearch.com/industry-analysis/prebiotics-market , Food & beverage was ...
(Date:10/30/2014)... Rock Hill, South Carolina (PRWEB) October 30, 2014 ... a muscle, and should be more vigorously exercised to ... Grewal. He recently authored the book ‘Dementia Express: Lose ... , The book uses counterintuitive reasoning and sometimes conflicting ... an obstacle course for the mind, a reader must ...
(Date:10/30/2014)... Seattle, WA (PRWEB) October 30, 2014 Sound ... their decision infographic that will assist people any time they ... people discover the right answer by leading them through a ... a resolution to their initial query. , There are many ... or not to use an answering service . This ...
Breaking Medicine News(10 mins):Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2
... Reporter , WEDNESDAY, Dec. 21 (HealthDay News) -- Problems in ... be at the heart of this learning disorder, new research ... issue of the journal Neuron , may one day ... diagnosed with this common yet still ultimately mysterious condition. ...
... HealthDay Reporter , WEDNESDAY, Dec. 21 (HealthDay ... protein shakes and soup followed by adding low-calorie, high-protein ... which may lessen joint pain and improve their quality ... might also help people whose obesity makes it impossible ...
... Dec. 21 (HealthDay News) -- Ludwig van Beethoven was arguably one ... he was deaf by the end of his career. Now, ... suggests that the progression of his deafness may have shaped his ... Netherlands analyzed three styles of Beethoven,s compositions. In a letter to ...
... induce a rapid weight decline, mainly in the first ... regain, despite continued dieting. The partial regain may ... now shows that improvements to health remain even if ... online in Diabetes Care (Print: February 2012) ...
... 50 per cent more likely to be admitted to hospital ... a study has found. Scots of Indian and Pakistani ... both conditions than people of white Scottish ethnicity. Those ... to hospital with chest pain compared with white Scots, according ...
... beef can contribute to a heart-healthy diet in the same ... DASH diet -- Dietary Approaches to Stop Hypertension -- is ... and reduce risk of heart disease. People following the DASH ... much beef. According to the Centers for Disease Control about ...
Cached Medicine News:Health News:Scientists Probe the Origins of Dyslexia 2Health News:Diet Might Help Those Immobilized by Knee Osteoarthritis 2Health News:Diet Might Help Those Immobilized by Knee Osteoarthritis 3Health News:Did Beethoven's Hearing Loss Shape His Compositions? 2Health News:More reasons to keep this New Year's weight loss resolution uncovered by Ben-Gurion U researchers 2Health News:More reasons to keep this New Year's weight loss resolution uncovered by Ben-Gurion U researchers 3Health News:Heart disease study highlights Scottish ethnic groups most at risk 2Health News:Having a cow can be a heart healthy choice 2
... is a monomeric protein produced and stored ... GH is released from the pituitary into ... the regulatory control of hypothalamic somatostatin (SS) ... and frequency of GH release appears to ...
... or somatomedin C) is a 7.6 kDa peptide ... a potent mitogen of cellular proliferation, exerting its ... the circulation, IGF-I is bound to IGF-binding proteins ... IGF-I by modulating the interaction of IGF-I with ...
... Insulin-like growth factor I (IGF-I or somatomedin ... in the liver. It acts as a potent ... binding to specific cell-surface receptors. In the circulation, ... appear to regulate the actions of IGF-I by ...
... a potent naturally occurring androgen produced ... cholestenone 5a-reductase [1]. The concentrations ... peripheral tissues, including genital skin and ... in apparent association with the nuclear ...
Medicine Products: